The Map Isn’t the Milestone. What It Unlocks Is.

By Jared Bauer, CEO

Seek Labs recently announced BioSeeker has mapped CRISPR-addressable regions across all 25 viral families known to infect humans.

That is an important infectious disease milestone. It gives us a comprehensive atlas of potential viral vulnerabilities that can be evaluated across known pathogens, emerging variants, and future threats. But the map itself is not what excites me most.

What matters is what the milestone demonstrates: our ability to take an enormous biological landscape, analyze it systematically, and turn it into prioritized opportunities for potential therapeutics and diagnostics. These are opportunities that, if realized, could reach patients faster, address diseases that have been overlooked, and improve outcomes where options are limited.

We did not build BioSeeker simply to describe biology. We built it to help us decide what to build next, and, ultimately, to help more patients receive better answers.

Discovery has historically forced us to leave too much biology unexplored

Many of the world’s most consequential diseases are driven or defined by genetic sequences. Within those sequences are instructions and dependencies: these allow viruses to replicate and spread or for cancer cells to survive, proliferate, and resist intervention. Identifying the right sequence is one of the earliest and most consequential decisions in developing a therapeutic or diagnostic product.

For patients, that early decision can shape everything that follows: whether a treatment works, how broadly it applies, how quickly it can be developed, and whether it reaches them at all.

Historically, that work has been slow, expensive, and heavily manual. Researchers may spend months or years studying a disease, comparing targets, testing hypotheses, and determining where an intervention might have the greatest effect. That process has produced extraordinary advances. It has also imposed real limits.

Consider Ebola. Vaccines have been developed against Zaire ebolavirus, the species responsible for previously recorded outbreaks. But these vaccines are not currently licensed for Bundibugyo virus, another member of the same genus, and evidence of cross-protection remains uncertain. When a related virus emerges, patients may still face delays while new countermeasures are evaluated, adapted, and validated under pressure.

When discovery is expensive and must largely be rebuilt for each new program, only a fraction of the biological opportunities in front of us can be pursued. A disease may receive too little attention because its market is small, its patients are geographically dispersed, its biology is considered too difficult, or the traditional development path is simply too costly.

For patients, that often translates into fewer treatment options, slower progress, and in some cases, no viable solutions at all. The problem is not a lack of important diseases. The problem is that we have historically lacked the capacity to evaluate enough of them.

BioSeeker is designed to begin changing that equation. It analyzes large collections of genomic sequences to identify conserved and functionally important regions, screen potential candidates for specificity, and rank designs for further development. Those outputs can then feed into our therapeutic and diagnostic product platforms.

BioSeeker does not replace the rigorous work of scientists, nor does it eliminate the difficult work of biological validation. But it does give scientists a much more powerful place to begin, so promising ideas can reach patients sooner and more consistently.

Turning target discovery into product design

Traditional discovery often starts with an open-ended search. Where can we intervene? Which target matters most? Which sequence is sufficiently conserved? Which design may provide the desired breadth without creating unacceptable off-target concerns? BioSeeker allows more of that search to become a structured design process.

The platform can evaluate the genetic landscape of a disease, identify sequences the disease may be least able to change without losing essential function, screen out weaker candidates, and prioritize designs based on characteristics such as conservation, breadth, durability, specificity, and strategic need.

The result is not a finished drug or diagnostic. It is something earlier but enormously valuable: a set of ranked, actionable product opportunities that can advance into laboratory validation.

For patients, this matters because it can reduce the time spent pursuing less promising paths and increase the likelihood that the most effective interventions are identified and developed. That changes the scale of the questions we can ask.

• -Can we evaluate an entire category of disease rather than searching for one target at a time?
• -Can the same discovery process identify both therapeutic and diagnostic opportunities?
• -Can rare and neglected diseases be evaluated using the same infrastructure as major commercial indications?

Those are questions about whether biotechnology discovery itself can become more systematic, scalable, and productive, and whether more patients, across more disease types, can benefit from that progress.

Twenty-five viral families create a much larger opportunity landscape

BioSeeker’s atlas of viruses is not one product. It is not even 25 products. Each viral family includes different genera, species, strains, and variants. Across that landscape may be opportunities for pathogen-specific interventions, broader approaches that address multiple related viruses, multiplexed designs intended to reduce viral escape, molecular diagnostics, veterinary applications, public health tools, and research products.

This breadth matters for patients. It means the potential for treatments that are not limited to a single strain, diagnostics that remain effective as viruses evolve, and faster responses when new threats emerge.

Not every target will become a product. Many candidates will fail experimental validation. Others may prove difficult to deliver, manufacture, regulate, or commercialize. Some will be scientifically interesting but strategically impractical. This is the reality of biotechnology. But we can now begin evaluating these opportunities systematically.

The atlas allows us to compare target density, conservation, potential coverage, and strategic importance across a biological landscape that would be extraordinarily difficult to assess manually. We can use that intelligence to decide which programs should move forward internally, which may be best developed with partners, and which we should hold back for future development.

That is how a discovery engine begins to become a pipeline engine; it’s also how more potential treatments can move more rapidly from concept toward patients.

One engine, multiple product paths

BioSeeker is not limited to producing one kind of output. A conserved disease sequence may have different applications depending on how the underlying genomic intelligence is deployed.

For therapeutics, BioSeeker can generate guide designs that may advance through our Programmable Target Ablation Platform (PTAP™) and toward disease-specific Sequence Ablation Therapeutic candidates. For molecular diagnostics, the same genomic intelligence can inform the design of primers and probes intended to detect diseases across relevant strains and variants. A single mapping effort can create more than one development path. For patients, this can translate into both earlier detection and more precise treatment, two factors that are often critical to improving outcomes.

The knowledge generated from the atlas and validated through laboratory and product development can then return to the system and improve how future targets are identified, ranked, and designed. Over time, that compounding effect may be more important than the speed of any single analysis because it can continuously improve how quickly and effectively new solutions reach patients.

Beyond infectious disease

We announced the viral atlas because that is the milestone BioSeeker has now reached, but the underlying architecture is not limited to viruses. BioSeeker is designed around sequence-driven disease. We are applying this architecture to pathogen genomes and human cancer sequences, while PTAP is being developed as a programmable foundation across RNA viruses, DNA viruses, and oncogenes.

The biological challenges across these diseases are not identical. In infectious disease, the target may be a sequence a pathogen depends on to replicate. In oncology, the target may be a cancer-driving sequence that malignant cells depend on for survival, proliferation, or treatment resistance.

The delivery requirements are different. The safety considerations are different. The experimental and clinical pathways are different. But the foundational question remains consistent: which genetic sequence or dependency is essential to the disease, and can we design a precise intervention against it? Answering this question more effectively could mean therapies that are more targeted, more durable, and potentially more effective against diseases that have been difficult to treat.

The long-term value of this platform is not confined to a single therapeutic pipeline or diagnostic product. It is the ability to repeatedly translate biology into designs that can be deployed through multiple technologies and across multiple disease areas, expanding the number of patients who may benefit.

AI can change the economics of biotechnology

There are countless diseases that need better solutions. But biotechnology has always required difficult choices because each new program demands specialized expertise, infrastructure, capital, time, and risk. When the earliest stages of discovery must be recreated for every indication, many promising opportunities never receive serious consideration. For patients, that often means waiting longer, or indefinitely, for new treatments. A shared, AI-powered discovery engine can make part of that work more scalable.

The same computational architecture can analyze another pathogen, another oncogene, or another disease sequence without requiring the organization to expand proportionally with every new question. It can help prioritize targets, produce designs, compare opportunities, and route the strongest candidates toward different product platforms.

This does not necessarily make biotechnology easy: laboratory validation, delivery, manufacturing, toxicology, clinical development, and regulatory review still require enormous discipline, time, and capital. Computational confidence is not the same as biological proof. But AI can help us reach the right experiments sooner.

AI can help eliminate weaker candidates earlier. It can allow a relatively small team to evaluate a biological landscape that would previously have required far more people, time, and money. Most importantly, it can make more opportunities practical to investigate, so that more diseases, including rare and underserved ones, have a realistic path toward treatment.

What this milestone demonstrates

Mapping all 25 viral families known to infect humans does not mean we have created a treatment for every virus. It does not mean that every computational design will become a viable product. The milestone demonstrates something different.

We can now operate at a scale that would have been extraordinarily difficult through traditional discovery alone. We can organize a vast biological landscape into prioritized and actionable target opportunities. And we can use a single discovery engine to support multiple product paths. This scale matters for patients.

• -It means the potential for faster responses to emerging outbreaks.
• -It means more sustained progress against long-standing infectious diseases.
• -It means new approaches to cancers that remain extraordinarily difficult to treat.
• -It means that diseases which have historically been overlooked may finally receive meaningful attention.

What matters more are the products, partnerships, and possibilities that can be built from it, as well as the patients those efforts are ultimately intended to serve. This is not simply about preparing for the next outbreak. It is about building a new way to discover products across infectious disease, oncology, and other areas of sequence-driven disease. It is also about using AI to explore more biology, evaluate more opportunities, and move the strongest ideas into the laboratory faster and with greater precision. Most importantly, it is about creating more opportunities to deliver better answers to patients who are still waiting for them.

Seek Labs’ therapeutic and diagnostic candidates are investigational and have not been approved, cleared, or authorized by the U.S. Food and Drug Administration or any other regulatory authority. They are not available for clinical diagnostic or therapeutic use. Forward-looking statements regarding potential products, applications, development plans, and platform capabilities are subject to risks and uncertainties.